A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS) (OptIMize)
A Randomized, Single-Blind, Multicenter Phase 4 Trial Evaluating Two Imetelstat Doses in Participants With Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS)
This study is testing two doses of imetelstat in adults with lower-risk myelodysplastic syndrome, or MDS. The study will include about 100 adults in several countries. To be eligible, participants must have lower-risk MDS, need frequent red blood cell transfusions, and have already tried-or cannot use-other treatments for anemia. Participants will be randomly placed into one of two groups. One group will receive the usual dose of imetelstat, 7.1 mg/kg of body weight. The other group will receive a lower dose, 3.55 mg/kg. Both doses are given through a vein during a roughly two-hour clinic visit every four weeks. Participants won't be told which dose they receive, but their study doctors and the study sponsor will know.
The main goal is to learn whether the lower dose can be safer while still reducing transfusion needs.
Blood tests will be done often, especially early in treatment. If blood counts fall too much or other serious side effects occur, treatment may be delayed, lowered, or stopped. Participants in the lower-dose group who have no clear benefit after at least six treatment cycles may be allowed to move to the higher dose if they meet safety requirements. Study treatment can continue until the disease gets worse, side effects become too severe, patient chooses to stop, or the study ends. Study visits include blood tests, physical exams, vital signs, reviews of transfusions and side effects, and sometimes cardiac or bone marrow tests. Investigators will also collect extra blood samples to study imetelstat pharmacokinetic and how it affects blood cells and MDS-related genes.
Taking part is voluntary. Participants may leave the study at any time.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Michelle Mudge-Riley, DO
- Número de telefone: +1 (650) 473-7793
- E-mail: mds4001-info@geron.com
Estude backup de contato
- Nome: Khaja Syed, PhD
- Número de telefone: +1 (650) 473-7793
- E-mail: mds4001-info@geron.com
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Man or woman greater than or equal to (≥) 18 years of age
- Diagnosis of MDS according to World Health Organization (WHO) 2016 classification confirmed by bone marrow aspirate and biopsy within 6 months prior to randomization that meets revised IPSS-R classification of very low, low, or intermediate risk disease
- RBC transfusion dependent, defined as requiring at least 4 RBC units transfused over an 8-week period during the 16 weeks prior to randomization; pre-transfusion Hgb should be ≤ 9.0 g/dL to count towards the 4 units total.
- Relapsed/refractory to, or ineligible for, erythropoiesis-stimulating agent (ESA) (EPO levels > 500 or per local guidelines); or Relapsed/refractory to, or ineligible for, erythroid maturation agent (EMA) (such as luspatercept) and has an endogenous serum EPO level >200 mU/mL at time of screening.
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Exclusion Criteria:
- Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients
- Prior treatment with imetelstat
- Participant has received an experimental or investigational drug or used an invasive investigational medical device within 30 days of randomization
- Has received corticosteroids greater than (>) 30 milligram per day (mg/day) prednisone or equivalent within 4 weeks prior to randomization, or growth factor treatment for a 7-day period or 7 half-lives of growth factor used prior to randomization, whichever is longer.
- Has received ESA or EMA therapy within 4 weeks prior to randomization (8 weeks for long-acting ESAs) or any chemotherapy, immunomodulatory or immunosuppressive therapy, within 4 weeks prior to randomization
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Outro: Arm A: imetelstat 7.1 mg/kg
Participants will receive imetelstat at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study. |
imetelstat will be given intravenously at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study. |
|
Experimental: Arm B: imetelstat 3.55 mg/kg
Participants will receive imetelstat at 3.55 mg/kg intravenous (IV) every 28days (±3 days), until disease progression or unacceptable toxicity, withdrawal of treatment or end of study. |
imetelstat will be given intravenously at 3.55 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of ≥ 12-week Red Blood Cell Transfusion Independence (RBC TI) with concurrent mean Hgb rise of at least 1.5 g/dL
Prazo: Weeks 1-24
|
Proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any |
Weeks 1-24
|
|
Rate of Grade 3/4 thrombocytopenia by laboratory values
Prazo: Weeks 1-24
|
Proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 thrombocytopenia events by laboratory values before subsequent anticancer therapy or dose escalation if any |
Weeks 1-24
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of ≥ 12 weeks RBC TI
Prazo: Weeks 1-24
|
Proportion of participants without any RBC transfusion during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any |
Weeks 1-24
|
|
Rate of ≥ 12 weeks RBC TI with concurrent mean Hgb rise of at least 1.5 g/dL
Prazo: Up to End of Study (approximately 3.5 years)
|
It is defined as the proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) at any time starting from randomization until subsequent anticancer therapy or dose escalation if any. |
Up to End of Study (approximately 3.5 years)
|
|
Rate of RBC TI ≥ 8 weeks, ≥12 weeks, ≥ 16 weeks, or ≥ 24 weeks
Prazo: Up to End of Study (approximately 3.5 years)
|
Proportion of participants without any RBC transfusion during any consecutive 8, 12, 16, or 24 weeks (56, 84, 112, or 168 days) respectively at any time starting from randomization until subsequent anti-cancer therapy or dose escalation if any |
Up to End of Study (approximately 3.5 years)
|
|
Duration of RBC TI Response
Prazo: Up to End of Study (approximately 3.5 years)
|
Duration of RBC TI defined as the first day of the longest RBC TI period to the date of the first RBC transfusion after the TI period started. |
Up to End of Study (approximately 3.5 years)
|
|
Time to RBC TI Response
Prazo: Up to End of Study (approximately 3.5 years)
|
It is defined as the interval from randomization to the first day of corresponsive RBC TI response |
Up to End of Study (approximately 3.5 years)
|
|
Hgb peak and rise
Prazo: Up to End of Study (approximately 3.5 years)
|
Hgb peak defined as the maximum Hgb value excluding values that were within 14 days after transfusion. Hgb rise defined as the difference between the Hgb peak and the pretreatment Hgb level |
Up to End of Study (approximately 3.5 years)
|
|
Rate of Hgb rise of at least 1.5 g/dL lasting ≥ 12 weeks
Prazo: Up to End of Study (approximately 3.5 years)
|
Defined as the proportion of participants who had Hgb rise lasting at least 12 weeks during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any |
Up to End of Study (approximately 3.5 years)
|
|
Rate of Hematologic Improvement Including Erythroid Response (HI-E) as Per International Working Group (IWG) Response Criteria 2018
Prazo: Up to End of Study (approximately 3.5 years)
|
For low transfusion burden participants (who received 3 to 7 RBC units in the 16 weeks prior to trial entry): Clinically meaningful HI-E response per revised IWG 2018 is defined as 16-week RBC TI, i.e., participants without any RBC transfusion during any consecutive 16 weeks. For high transfusion burden participants (who received ≥ 8 RBC units in the 16 weeks prior to trial entry):
|
Up to End of Study (approximately 3.5 years)
|
|
Rate of disease progression, including AML progression
Prazo: Up to End of Study (approximately 3.5 years)
|
Proportion of participants who had disease progression (or AML progression) per modified IWG 2006 criteria |
Up to End of Study (approximately 3.5 years)
|
|
Rate of Grade 3/4 neutropenia by laboratory values
Prazo: Weeks 1-24
|
Defined as the proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 neutropenia events by laboratory values before subsequent anticancer therapy or dose escalation, if any |
Weeks 1-24
|
|
Treatment Emergent Adverse Events (TEAEs)
Prazo: Up to End of Study (approximately 3.5 years)
|
Incidence, severity, and type of treatment emergent adverse events (TEAEs, with a specific focus on bleeding and infection events), and other clinical laboratory values (including liver function test [LFT] abnormalities) |
Up to End of Study (approximately 3.5 years)
|
|
Time to Resolution of Lab Events
Prazo: Up to End of Study (approximately 3.5 years)
|
Time to resolution of Grade ≥ 3 neutrophil and platelet counts to baseline grade after end of dosing. |
Up to End of Study (approximately 3.5 years)
|
|
Assessment of Plasma concentrations of imetelstat
Prazo: Cycles 1-6 (28 day cycles)
|
Concentrations of imetelstat in Plasma |
Cycles 1-6 (28 day cycles)
|
|
Assessment of Cmax
Prazo: Cycles 1-6 (28 day cycles)
|
Maximum Observed Plasma Concentration (Cmax) |
Cycles 1-6 (28 day cycles)
|
|
Assessment of AUC
Prazo: Cycles 1-6 (28 day cycles)
|
Area under the drug concentration-plasma time curve (AUC) from time zero to last measurable concentration |
Cycles 1-6 (28 day cycles)
|
|
Population PK/PD Model-Predicted Rates of Grade 3/4 Thrombocytopenia, Grade 3/4 Neutropenia, and Mean ≥1.5 g/dL Hemoglobin Increase Sustained for ≥12 Weeks
Prazo: Cycles 1-6 (28 day cycles)
|
Cycles 1-6 (28 day cycles)
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to acute myeloid leukemia (AML) progression among participants with documented AML progression
Prazo: Up to End of Study (approximately 3.5 years)
|
Up to End of Study (approximately 3.5 years)
|
|
|
Assessment of biomarkers
Prazo: Cycles 1-2 (28 day cycles)
|
At baseline and change from baseline |
Cycles 1-2 (28 day cycles)
|
|
Assessment of Mutation status
Prazo: Up to End of Study (approximately 3.5 years)
|
At baseline and change from baseline including at the time of suspected progression |
Up to End of Study (approximately 3.5 years)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Diretor de estudo: Joseph E Eid, MD, Geron Corporation
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- MDS4001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .